Clinical effectiveness of Biqi capsule combined with methotrexate in rheumatoid arthritis: an integrated retrospective, meta-analytic, and machine learning study
Klinische Wirksamkeit von Biqi-Kapsel kombiniert mit Methotrexat bei rheumatoider Arthritis: integrierte retrospektive, Metaanalyse- und Machine-Learning-Studie
Frontiers in Immunology · 11.11.2026 · 17
DOI: 10.3389/fimmu.2026.2000963 ↗Auf einen Blick
Bei rheumatoider Arthritis war die Kombination aus Biqi-Kapsel und Methotrexat in einer Kohorte und in der Metaanalyse mit günstigeren Entzündungs- und klinischen Parametern verbunden. Die Sicherheitsraten unterschieden sich nicht signifikant.
Fragestellung
Welche klinischen Effekte hat Biqi-Kapsel zusätzlich zu Methotrexat bei rheumatoider Arthritis?
Methode
Retrospektive Kohortenstudie, explorative Machine-Learning-Analyse und systematische Übersichtsarbeit mit Metaanalyse.
Ergebnisse
100 Patient:innen in der Kohorte; 24 (48,0 %) in der Kombinationsgruppe erfüllten das serologische Ansprechkriterium. Metaanalyse: 9 Studien mit 952 Teilnehmenden; RF, ESR, CRP, Morgensteifigkeit, druckschmerzhafte und geschwollene Gelenke sowie klinisches Ansprechen besser; UAW ohne signifikanten Unterschied.
Einschränkungen
Residual confounding, begrenzte Modellgüte und Heterogenität zwischen den Studien.
Schlussfolgerung der Autor:innen
Biqi-Kapsel könnte zusätzlich zu Methotrexat Vorteile bieten. Die Autor:innen betonen jedoch, dass weitere prospektive multizentrische Studien und externe Validierung nötig sind.
Kernaussagen
- Kohorte: Anti-CCP nach 24 Wochen unter Kombination niedriger als unter MTX allein
- Metaanalyse: bessere RF-, ESR-, CRP- und klinische Werte unter BQC-basierten Regimen
- Keine signifikanten Unterschiede bei unerwünschten Ereignissen
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Immunology, online erschienen am 11.11.2026. Verfasst von Chenguang Zhan und 15 weiteren Autor:innen. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Methotrexate (MTX) monotherapy provides inadequate disease control in many patients with rheumatoid arthritis (RA). Biqi Capsule (BQC), a proprietary traditional Chinese medicine formulation, is used as an adjunct to MTX, but its clinical benefits remain uncertain.
Methods
We evaluated Biqi Capsule plus MTX by integrating a retrospective cohort study, exploratory machine-learning analysis, and a systematic review and meta-analysis. The cohort comprised 100 patients who received either MTX monotherapy (n = 50) or Biqi Capsule plus MTX (n = 50).
Results
After adjustment for the corresponding baseline values, anti-cyclic citrullinated peptide antibody (anti-CCP) levels at week 24 were lower in the combination-therapy group than in the MTX monotherapy group ( P = 0.002), whereas other inflammatory markers and liver and kidney function indices showed no significant between-group differences. Among patients receiving combination therapy, 24 (48.0%) met the prespecified serological response criterion, defined as a ≥25% reduction in anti-CCP levels from baseline. Among the eight algorithms evaluated, the bagged trees model achieved the highest area under the receiver operating characteristic curve (AUC, 0.601; 95% confidence interval [CI], 0.445 to 0.752), with blood urea nitrogen (BUN), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) exhibiting the greatest permutation importance. This meta-analysis included nine studies involving 952 participants. Compared with the controls, BQC-based regimens were associated with significantly lower rheumatoid factor (RF), ESR, and CRP levels, shorter duration of morning stiffness, lower tender and swollen joint counts, and higher overall clinical response rates. The pooled analysis showed no significant between-group difference in the odds of adverse events. Subgroup analyses by treatment regimen showed significant pooled effects favoring BQC plus MTX over the controls for RF, ESR, CRP, morning stiffness duration, swollen joint count, and overall clinical response. Relative to their respective controls, the BQC plus MTX subgroup showed greater pooled reductions in RF and ESR than the BQC monotherapy subgroup, with significant between-subgroup differences.
Discussion
Overall, Biqi Capsule may offer additional benefits alongside MTX. However, residual confounding, modest model discrimination, and between-study heterogeneity limit firm conclusions. Larger prospective multicenter studies and independent external validation are warranted to confirm these findings.
Zitieren
APA
Zhan, C., Li, X., Yan, X., Liu, C., Li, H., Wang, T., Liu, X., Fan, C., Luo, T., Wang, M., Mei, L., Wu, X., Chen, X., Gao, K., Du, H., & Huang, R. (2026). Clinical effectiveness of Biqi capsule combined with methotrexate in rheumatoid arthritis: an integrated retrospective, meta-analytic, and machine learning study. Frontiers in Immunology, 17. https://doi.org/10.3389/fimmu.2026.2000963
Vancouver
Zhan C, Li X, Yan X, Liu C, Li H, Wang T, et al. Clinical effectiveness of Biqi capsule combined with methotrexate in rheumatoid arthritis: an integrated retrospective, meta-analytic, and machine learning study. Frontiers in Immunology. 2026;17. doi:10.3389/fimmu.2026.2000963
BibTeX
@article{Zhan2026,
author = {Zhan, Chenguang and Li, Xin and Yan, Xingrui and Liu, Chibin and Li, Haishan and Wang, Tao and Liu, Xingzheng and Fan, Chunxiao and Luo, Tingting and Wang, Maojie and Mei, Liyan and Wu, Xiaodong and Chen, Xiumin and Gao, Kaixin and Du, Haifang and Huang, Runyue},
title = {Clinical effectiveness of Biqi capsule combined with methotrexate in rheumatoid arthritis: an integrated retrospective, meta-analytic, and machine learning study},
journal = {Frontiers in Immunology},
year = {2026},
volume = {17},
doi = {10.3389/fimmu.2026.2000963}
}
EUVIMED